Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janne Kaern

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Gynecologic Oncology|July 21, 2004
Kallikrein 4 is associated with paclitaxel resistance in ovarian cancerZhijun Xi, Janne Kaern, Ben Davidson, et al.
Molecular Cancer|February 6, 2007
Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markersChristina E Hoei-Hansen, Sigrid M Kraggerud, Vera M Abeler, et al.
Cancer Genetics and Cytogenetics|November 6, 2004
Evaluation of genomic changes in a large series of malignant ovarian germ cell tumors--relation to clinicopathologic variablesWanja Kildal, Janne Kaern, Sigrid Marie Kraggerud, et al.
Gynecologic Oncology|October 12, 2005
The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinomaElin Ødegaard, Anne Cathrine Staff, Janne Kaern, et al.
Pathology|May 10, 2006
Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomasMorteza Aghmesheh, Zhenhe Suo, Michael Friedlander, et al.
Gynecologic Oncology|December 8, 2004
No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancersMorteza Aghmesheh, Jahn M Nesland, Janne Kaern, et al.
Gynecologic Oncology|November 23, 2016
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trialRoberto Sorio, Célia Roemer-Becuwe, Felix Hilpert, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Gynecologic Oncology|July 21, 2004
Kallikrein 4 is associated with paclitaxel resistance in ovarian cancerZhijun Xi, Janne Kaern, Ben Davidson, et al.
Molecular Cancer|February 6, 2007
Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markersChristina E Hoei-Hansen, Sigrid M Kraggerud, Vera M Abeler, et al.
Cancer Genetics and Cytogenetics|November 6, 2004
Evaluation of genomic changes in a large series of malignant ovarian germ cell tumors--relation to clinicopathologic variablesWanja Kildal, Janne Kaern, Sigrid Marie Kraggerud, et al.
Gynecologic Oncology|October 12, 2005
The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinomaElin Ødegaard, Anne Cathrine Staff, Janne Kaern, et al.
Pathology|May 10, 2006
Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomasMorteza Aghmesheh, Zhenhe Suo, Michael Friedlander, et al.
Gynecologic Oncology|December 8, 2004
No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancersMorteza Aghmesheh, Jahn M Nesland, Janne Kaern, et al.
Gynecologic Oncology|November 23, 2016
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trialRoberto Sorio, Célia Roemer-Becuwe, Felix Hilpert, et al.
Pageof 2